Jane Street’s AgomAb Therapeutics NV AGMB Stock Holding History

Jane Street’s Portfolio AGMB Stock Details AGMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,794	Closed	-$134K	–	13821
2026 Q1	$134K	Buy	+12,794	New	+$181K	﹤0.01%	10469

Other funds holding AGMB

EFM

EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Andera Partners Paris $206M AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jane Street's AGMB Position: Q2 2026 in Review

Jane Street sold out of AgomAb Therapeutics NV (AGMB) in Q2 2026, closing a stake of 12,794 shares — an estimated $134K sold.

Jane Street first reported a position in AGMB in Q1 2026 and held it in 1 quarter. The position peaked at $134K in Q1 2026. 34 funds tracked by Wall St. Rank hold AGMB as of Q2 2026.

Jane Street reported no remaining AgomAb Therapeutics NV position as of Q2 2026 after selling out during the quarter.
Jane Street sold 12,794 AgomAb Therapeutics NV shares in Q2 2026, an estimated $134K.
Jane Street first reported a position in AgomAb Therapeutics NV in Q1 2026 and held it in 1 quarter.
Jane Street's AgomAb Therapeutics NV position peaked at $134K in Q1 2026.
34 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.